7. Coagulopathy (General Framework: Anticoagulant Reversal, HIT, Uremic Bleeding, Hepatic Coagulopathy)

Quick Recap

Hematology System, Protocol 8/8 — completing the Hematology System. Covers the general coagulopathy differential and management not already addressed by the dedicated DIC, TTP, HUS, and Massive Transfusion protocols: anticoagulant reversal, uremic bleeding, HIT, and liver disease-associated coagulopathy.

1. Diagnostic Framework — Clinical Recognition Drives Therapy Choice

Common ICU causes of thrombocytopenia/coagulopathy: drug-induced (heparin, H2-receptor blockers, GP2b3a inhibitors, antibiotics, alcohol), sepsis, massive bleeding/dilution, and thrombocytopenia WITH microangiopathic hemolytic anemia (TTP, HUS, DIC — see dedicated protocols). Clinical recognition of the specific cause is vital, as therapies differ considerably — a patient with dilutional/bleeding-related thrombocytopenia should be treated with platelets, while a patient with TTP/HUS should generally NOT receive platelet transfusion (see those dedicated protocols) and instead needs plasmapheresis or eculizumab. Applying the wrong therapy for the wrong mechanism can actively harm the patient, making correct diagnosis the first and most important step before reaching for any blood product.

2. Coagulation Panel Interpretation Reference

3. Anticoagulant Reversal

Warfarin (vitamin K antagonist): vitamin K 10mg IV/enteral daily x3 days PLUS PCC preferred over FFP for rapid reversal in bleeding/urgent-procedure patients — faster onset, less volume than FFP. PCC dosing by INR: 2-3.9 = 25 units/kg (max 2500); 4-6 = 35 units/kg (max 3500); >6 = 50 units/kg (max 5000). FFP 15-20mL/kg as an alternative if PCC unavailable. In the ABSENCE of bleeding, do NOT correct an elevated INR with FFP — consider whether vitamin K deficiency (poor intake, antibiotics, anticoagulant use) is the driver instead, which responds to IV vitamin K supplementation alone.

LMWH (last dose <8h): protamine 1mg per 100 anti-Xa units (max 50mg).

Dabigatran (direct thrombin inhibitor): idarucizumab 5g IV once — specific, rapid reversal.

Apixaban/rivaroxaban (factor Xa inhibitors): activated charcoal if last dose <2h; andexanet alfa (low-dose 400mg bolus + 4mg/min infusion if >8h from last dose; high-dose 800mg bolus + 8mg/min infusion if <8h from last dose) — superiority over PCC has NOT been firmly established; PCC 50 units/kg (max 5000) as a reasonable, more widely available alternative.

Heparin (unfractionated): protamine sulfate, dosed to the estimated circulating heparin activity (1mg protamine per 100 units heparin, adjusted for time since last dose given heparin's short half-life).

4. Heparin-Induced Thrombocytopenia (HIT)

Type 1 HIT: modest, transient platelet decline within 2-3 days of heparin start, nadir generally above 100,000/mcL, spontaneously resolving, NOT associated with clinical complications — a benign, non-immune phenomenon distinct from Type 2.

Type 2 HIT (the clinically significant form): immune-mediated, antibodies against the heparin-platelet factor 4 (PF4) complex — can be triggered by UNFRACTIONATED or LOW-MOLECULAR-WEIGHT heparin. Key diagnostic clues: platelet count decline >50% occurring 5-10 days after FIRST heparin exposure (more rapid decline with prior heparin exposure, given pre-existing antibody); platelet count often well below 100,000/mcL, typically WITHOUT clinical bleeding (a paradoxical thrombocytopenic-but-PROTHROMBOTIC state, not primarily a bleeding disorder); may develop erythema/necrosis at heparin injection sites; systemic symptoms (fever, wheezing, tachycardia) possible with heparin boluses.

Diagnostic workup: ELISA assay for anti-PF4 antibody, serotonin release assay, platelet aggregation studies; Doppler ultrasound to screen for thrombosis given HIT's prothrombotic (not primarily hemorrhagic) nature.

Management: STOP all heparin products immediately (including heparin flushes, heparin-coated catheters) upon confirmed/strongly suspected Type 2 HIT. Use direct thrombin inhibitors (argatroban, lepirudin) for ongoing anticoagulation need — fondaparinux should be used with CAUTION; LMWH and unfractionated heparin should NOT be used (LMWH cross-reacts with the same PF4 antibody in most cases, so switching from UFH to LMWH is NOT an acceptable substitution).

5. Uremic Bleeding

Pathophysiology: multifactorial platelet DYSFUNCTION (not primarily thrombocytopenia) — accumulated uremic toxins (e.g., guanidinosuccinic acid) inhibit platelet activation/aggregation; elevated nitric oxide and prostacyclin impair platelet-endothelial adhesion and platelet-platelet interaction. The defect resides in the PLASMA ENVIRONMENT, not the platelets themselves — demonstrated by cross-over experiments (uremic platelets in normal plasma function normally; normal platelets in uremic plasma acquire the defect). Anemia itself contributes to bleeding by altering blood rheology (platelets flow more centrally away from the vessel wall in anemic blood, reducing their interaction with an injured vessel wall).

Presentation: mucosal bleeding predominates — gingival bleeding, epistaxis, hematuria; CNS/severe GI bleeding less common but possible. PT and aPTT are usually NORMAL when uremia is the cause — a normal coagulation panel in a bleeding renal failure patient should raise uremic platelet dysfunction as the mechanism, not be reassuring against a bleeding diathesis.

Management:

• Hemodialysis/peritoneal dialysis is the MOST EFFECTIVE treatment, removing the causative uremic toxins directly — the preferred, definitive intervention
• RBC transfusion to correct anemia decreases bleeding acutely (via the rheologic mechanism above), a genuinely useful adjunct beyond simply correcting oxygen-carrying capacity
• Platelet transfusion is GENERALLY NOT EFFECTIVE — transfused platelets rapidly acquire the same dysfunction once exposed to the uremic plasma environment, making the effect transient and platelet transfusion a poor primary strategy in this specific condition
• Desmopressin (DDAVP) increases plasma factor VIII, vWF, and tissue plasminogen activator — used by some for uremic bleeding, though this is an OFF-LABEL indication

6. Liver Disease-Associated Coagulopathy

Note: liver disease produces a REBALANCED, not simply "deficient," coagulation state — both PRO-coagulant factor synthesis (II, V, VII, IX, X, fibrinogen) AND ANTI-coagulant protein synthesis (protein C, protein S, antithrombin) are reduced in parallel, meaning standard PT/INR elevation does NOT necessarily indicate a net bleeding tendency the way it does in isolated factor deficiency — do not reflexively correct an elevated INR in a cirrhotic patient without active bleeding or a planned invasive procedure, mirroring (and for a mechanistically distinct reason reinforcing) the general "don't correct labs without bleeding" principle from Sections 3 and elsewhere in this library.

When correction IS appropriate (active bleeding or pre-procedure): FFP can be considered for PT >1.5x upper normal value; initial dose 10-15 mL/kg (~4-6 units). For thrombocytopenia: 1 unit single-donor platelets (or 4 units random platelet concentrate), guided by post-transfusion count. Cryoprecipitate typically given in pools up to 10 units (providing ~1,500-2,000mg fibrinogen in 150mL) for hypofibrinogenemia. In the ABSENCE of active bleeding, prophylactic FFP/cryoprecipitate/platelet transfusion has NOT been shown to reduce bleeding risk or improve outcomes and should be AVOIDED — the same principle established in the DIC protocol applies with equal force here.

Recombinant factor VIIa (rFVIIa): reserved for rare cases where bleeding is not controlled despite adequate blood product resuscitation — associated with clinically significant thrombosis risk, use with caution; no well-defined dosing study exists for this off-label use, though 20-90 mcg/kg is generally cited as providing adequate hemostatic control when used.

7. Immediate Stabilization (ABCDE) — General Approach

Circulation: identify the specific coagulopathy mechanism (Sections 3-6, plus the DIC/TTP/HUS differential in their dedicated protocols) BEFORE choosing a blood product/reversal strategy — mechanism-mismatched therapy (e.g., platelets for TTP, LMWH for confirmed HIT) can actively worsen outcomes.

Checklist:

8. Investigations

Full coagulation panel per Section 2 (PT, aPTT, TT, fibrinogen, D-dimer, platelet count with peripheral smear), renal function (uremic bleeding context), liver function tests (hepatic coagulopathy context), anti-PF4 ELISA/serotonin release assay if HIT suspected, Doppler ultrasound for thrombosis screening if HIT confirmed/suspected, mixing studies if an inhibitor (e.g., lupus anticoagulant) is suspected.

9. Organ Support

Mechanism-specific reversal/replacement therapy per Sections 3-6; hemodialysis for uremic bleeding (definitive therapy, not just supportive); standard ICU supportive care; RRT per standard AKI indications if renal failure is the underlying driver.

10. Consultation Matrix

11. Monitoring Framework

Serial coagulation panel per the specific etiology's expected trend, platelet count trend (HIT surveillance in any heparin-exposed patient), Doppler surveillance for thrombosis if HIT confirmed, renal/liver function trend, bleeding site surveillance.

12. Complications

Thrombosis (HIT's paradoxical prothrombotic complication despite thrombocytopenia), recurrent/refractory bleeding if mechanism misdiagnosed and mismatched therapy applied, transfusion-related complications from unnecessary prophylactic product administration, anticoagulant-reversal-related thrombosis (particularly rFVIIa). Prevention: correct mechanism identification before treatment, immediate heparin cessation for confirmed/suspected HIT with non-cross-reactive alternative anticoagulation, avoiding prophylactic correction of non-bleeding coagulopathy across all etiologies. Rescue: dialysis for uremic bleeding, direct thrombin inhibitors for HIT-associated thrombosis, escalating blood product support for ongoing hemorrhage per the specific etiology's guidance.

13. Escalation & De-escalation

Escalate: ongoing bleeding despite mechanism-appropriate initial therapy -> reassess diagnosis (consider an unaddressed second process), escalate blood product/reversal support, consider rFVIIa as a last resort (hepatic coagulopathy) or dialysis intensification (uremic bleeding).

De-escalate: underlying cause addressed (dialysis for uremic bleeding, heparin cessation for HIT, hepatic synthetic function stabilizing), no active bleeding -> discontinue prophylactic correction attempts, transition to standard monitoring.

14. ICU Discharge Criteria

Coagulopathy mechanism identified and addressed, no active bleeding, HIT (if confirmed) on an appropriate non-cross-reactive anticoagulant with thrombosis surveillance completed, renal/hepatic function stable or on an established management trajectory.

15. Documentation & Medicolegal Checklist

16. Key Guidelines

Napolitano LM, Warkentin TE. Heparin-induced thrombocytopenia in the critical care setting: diagnosis and management. Crit Care Med. 2006;34(12):2898-2911. Rice TW, Wheeler AP. Coagulopathy in critically ill patients: part 1: platelet disorders. Chest. 2009;136(6):1622-1630.

17. Controversies

The threshold for FFP correction in liver disease coagulopathy (PT >1.5x normal) is a pragmatic guideline rather than derived from rigorous outcome trials, and given the "rebalanced hemostasis" understanding of cirrhotic coagulopathy, some experts argue standard PT/INR is a poor predictor of actual bleeding risk in this population, complicating threshold-based correction decisions generally. DDAVP for uremic bleeding remains off-label with a relatively limited formal evidence base despite common use. Andexanet alfa's superiority over PCC for factor Xa inhibitor reversal remains unestablished by head-to-head data.

18. References

1. Coagulation Disorders in Critical Illness (general coagulopathy, HIT, uremic bleeding, liver disease sections). Washington Manual of Critical Care, 4th ed, 2025 (Ch. 66).
2. Patil V, Amin N, Ambulkar R, Kulkarni A. Disseminated Intravascular Coagulation and Thrombocytopenia. ICU Protocols: A Step-wise Approach, 2nd ed. Springer; 2020 (Ch. 8).
3. Napolitano LM, Warkentin TE. Heparin-induced thrombocytopenia in the critical care setting: diagnosis and management. Crit Care Med. 2006;34(12):2898-2911.
4. Rice TW, Wheeler AP. Coagulopathy in critically ill patients: part 1: platelet disorders. Chest. 2009;136(6):1622-1630.

See also: DIC, TTP, HUS, Massive Transfusion (Hematology System) for the specific thrombotic microangiopathy and massive-hemorrhage coagulopathy management this general protocol complements; Acute Kidney Injury and CRRT Indications (Renal System) for the dialysis-as-definitive-therapy framework for uremic bleeding.